Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

被引：2
|
作者：
Knudsen, Trine A. [1 ]
Hansen, Dennis Lund [2 ]
Ocias, Lukas Frans [2 ]
Bjerrum, Ole Weis [3 ]
Brabrand, Mette [2 ]
Christensen, Sarah F. [1 ]
Eickhardt-Dalboge, Christina Schjellerup S. [1 ]
Ellervik, Christina [4 ,5 ,6 ,7 ,8 ]
El Fassi, Daniel [3 ,9 ]
Frederiksen, Mikael [10 ]
Kjaer, Lasse [1 ]
Kristensen, Thomas Kielsgaard [11 ]
Kruse, Torben A. [12 ]
Larsen, Morten Kranker [1 ]
Mourits-Andersen, Torben [13 ]
Overgaard, Ulrik Malthe [3 ]
Severinsen, Marianne Tang [14 ]
Skov, Vibe [1 ]
Sorensen, Anders Lindholm [1 ]
Stentoft, Jesper [15 ]
Starklint, Jorn [16 ]
de Stricker, Karin [11 ]
Thomassen, Mads [12 ]
Larsen, Thomas S. [2 ]
Hasselbalch, Hans Carl [1 ,9 ]
机构：
[1] Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark
[2] Odense Univ Hosp, Dept Hematol, Odense, Denmark
[3] Copenhagen Univ Hosp, Rigshosp, Dept Hematol, Copenhagen, Denmark
[4] Reg Zealand, Dept Data & Data Support, Soro, Denmark
[5] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark
[6] Reg Zealand, Dept Prod Res & Innovat, Soro, Denmark
[7] Boston Childrens Hosp, Dept Lab Med, Boston, MA USA
[8] Harvard Med Sch, Dept Pathol, Boston, MA USA
[9] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[10] Hosp Southern Jutland, Dept Hematol, Aabenraa, Denmark
[11] Odense Univ Hosp, Dept Pathol, Odense, Denmark
[12] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark
[13] Hosp South West Jutland, Dept Hematol, Esbjerg, Denmark
[14] Aalborg Univ Hosp, Dept Hematol, Aalborg, Denmark
[15] Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark
[16] Hosp West Jutland, Dept Hematol, Holstebro, Denmark
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-156445
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1794 / 1796
页数：3
相关论文
共 50 条
  • [1] Baseline quality of life and symptom burden characteristics of patients intolerant to hydroxyurea: Preliminary results from the MAJIC Trial
    Scherber, R.
    McMullin, M. F.
    Mead, A.
    Fox, S.
    Shah, M.
    Abdi-Moradi, S.
    Bell, H.
    Doueck, A.
    Aliman, S.
    Green, A.
    Wood, M.
    Ewing, J.
    Chen, F.
    Coppell, J.
    Knapper, S.
    Yap, C.
    Ahmed, I.
    Geyer, H.
    Mesa, R.
    Harrison, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 : 81 - 81
  • [2] Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials
    Mazza, Gina L.
    Mead-Harvey, Carolyn
    Mascarenhas, John
    Yacoub, Abdulraheem
    Hoffman, Ronald
    Kosiorek, Heidi E.
    Prchal, Josef T.
    Silver, Richard T.
    Barbui, Tiziano
    Dueck, Amylou C.
    Mesa, Ruben
    BLOOD, 2020, 136
  • [3] A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2
    Dam, Marc J. B.
    Pedersen, Rasmus K.
    Knudsen, Trine A.
    Andersen, Morten
    Ellervik, Christina
    Larsen, Morten Kranker
    Kjaer, Lasse
    Skov, Vibe
    Hasselbalch, Hans C.
    Ottesen, Johnny T.
    CANCER MEDICINE, 2023, 12 (04): : 4218 - 4226
  • [4] Hydroxyurea Treatment History and Quality of Life in Patients with Polycythemia Vera: Results from the MPN Landmark Survey in the United States
    Mesa, Ruben A.
    Miller, Carole B.
    Mascarenhas, John O.
    Thyne, Maureen
    Goldberger, Sara
    Paranagama, Dilan C.
    Parasuraman, Shreekant V.
    Fazal, Salman
    Naim, Ahrnad B.
    Mangan, James
    BLOOD, 2015, 126 (23)
  • [5] Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials
    Mazza, Gina L.
    Mead-Harvey, Carolyn
    Mascarenhas, John
    Yacoub, Abdulraheem
    Kosiorek, Heidi E.
    Hoffman, Ronald
    Dueck, Amylou C.
    Mesa, Ruben A.
    LANCET HAEMATOLOGY, 2022, 9 (01): : E38 - E48
  • [6] A randomized controlled trial of pegylated-interferon alpha-2b plus ribavirin vs interferon
    Pol, S
    Perronne, C
    Carrat, F
    Banisadr, F
    Morand, P
    Lunel, F
    Rosenthal, E
    JOURNAL OF HEPATOLOGY, 2003, 38 : 32 - 32
  • [7] The effect of video training on symptom burden, comfort level, and quality of life in hemodialysis patients: Clustered randomized controlled trial
    Duman, Halise Taskin
    Karadakovan, Ayfer
    PATIENT EDUCATION AND COUNSELING, 2024, 126
  • [8] Effects of exercise during and after neoadjuvant chemoradiation on symptom burden and quality of life in rectal cancer patients: a phase II randomized controlled trial
    Andria R. Morielli
    Normand G. Boulé
    Nawaid Usmani
    Keith Tankel
    Kurian Joseph
    Diane Severin
    Alysa Fairchild
    Tirath Nijjar
    Kerry S. Courneya
    Journal of Cancer Survivorship, 2023, 17 : 1171 - 1183
  • [9] Effects of exercise during and after neoadjuvant chemoradiation on symptom burden and quality of life in rectal cancer patients: a phase II randomized controlled trial
    Morielli, Andria R.
    Boule, Normand G.
    Usmani, Nawaid
    Tankel, Keith
    Joseph, Kurian
    Severin, Diane
    Fairchild, Alysa
    Nijjar, Tirath
    Courneya, Kerry S.
    JOURNAL OF CANCER SURVIVORSHIP, 2023, 17 (04) : 1171 - 1183
  • [10] Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis
    Kamal, Sanaa M.
    Ahmed, Amany
    Mahmoud, Sara
    Nabegh, Leila
    El Gohary, Iman
    Obadan, Isi
    Hafez, Tamer
    Ghoraba, Dahlia
    Aziz, Ahmed A.
    Metaoei, Mona
    LIVER INTERNATIONAL, 2011, 31 (03) : 401 - 411
12345